Loading company
Aquestive Therapeutics, Inc.
AQST · Nasdaq · ·
Next earnings: November 4, 2026
$4.67-1.6%Sep 29 close
- 1M
- -7.0%
- 6M
- +15.6%
- 1Y
- -16.5%
- 5Y
- +3.3%
AQST · Nasdaq · ·
Next earnings: November 4, 2026
$4.67-1.6%Sep 29 close
Aquestive Therapeutics, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $13.8M | $10M | +38.15% |
| Profit | -$22.9M | -$13.5M | -68.76% |
| Profit per share | -$0.18 | -$0.14 | -28.57% |
| Free Cash Flow | -$9.7M | -$8M | -20.35% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2026, and provided a strategic business update. “The epinephrine rescue market continues to grow and remains available for conversion from older medical device technology including autoinjectors,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
AQST-108 (epinephrine) topical gel is a topically delivered adrenergic agonist prodrug product candidate. Aquestive completed a first-in-human study for AQST-108 without any serious or topical adverse events observed. AQST-108 is based on Aquestive’s AdrenaVerse™ platform which contains a library of over twenty epinephrine prodrugs intended to control absorption and conversion rates across a variety of possible dosage forms and delivery sites.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aquestive Therapeutics, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Aquestive Therapeutics, Inc. has no earnings call transcript available.